Preliminary result of Onni Bidco's voluntary recommended public cash tender offer for all the shares in Innofactor Plc; The Offeror has decided that it will waive the minimum acceptance condition
Darolutamide plus androgen deprivation therapy significantly reduced the risk of radiological progression or death by 46% compared to placebo plus ADT in patients with metastatic hormone-sensitive prostate cancer
Onni Bidco Oy has received all necessary regulatory approvals for its voluntary recommended public cash tender offer for all the shares in Innofactor Plc